Clinical trials: Hepatitis C Virus (HCV)
Hepatitis C, Osteoporosis
Awareness of Osteoporosis in Patients With Hepatitis C Infection
Osteoporosis is a condition that describes compromised skeletal microarchitecture in general, with clinical signs of decreased bone mineral density.
- Conditions
- Hepatitis C, Osteoporosis, Osteoporosis Risk
- Trial name
- NCT05769400
- Testing
- Patient Participation Form
- Volunteers
- 400 people
- Sponsor
- Uskudar State Hospital
Hepatitis C Virus Infection
Sofosbuvir/Velpatasvir Fixed Dose Combination in Participants With Chronic Hepatitis C Virus Infection Who Have Received a Liver Transplant
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of sofosbuvir /velpatasvir (SOF/VEL) fixed-dose combination (FDC) in participants with chronic hepatitis C virus (HCV) who have received…
- Trial name
- NCT02781571
- Testing
- SOF/VEL
- Where
- 15 sites in Spain, Switzerland and 1 more
- Volunteers
- 79 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis C
Study to Evaluate the Treatment for Chronic Hepatitis C With Normal Transaminases in HIV Positive Patients
In the current practice patients with normal levels of ALT were not treated. However, a percentage of patients will present an advanced grade of fibrosis and cirrhosis.
- Trial name
- CONTRA (NCT01684787)
- Testing
- Peginterferon alfa-2a + ribavirin in normal ALT, Peginterferon alfa-2a + ribavirin in elevated ALT
- Where
- 18 sites in Spain
- Volunteers
- 80 people
- Sponsor
- Miguel Santin
Hepatitis C, Substance Abuse
Psychoeducation for Hepatitis and Alcohol Behaviors
The proposed project will apply a unique, effective family-responsive psychoeducation program, PsychoEducation Responsive to Families (PERF), for Hepatitis C Virus (HCV) treatment.
- Trial name
- NCT00598416
- Testing
- Family-Responsive Psychoeducation Program (PERF)
- Where
- United States
- Volunteers
- 556 people
- Sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Chronic Hepatitis C
Proof-of-concept Study to Evaluate the Safety and Immunomodulatory Effects of SCV 07 as Monotherapy or in Combination With Ribavirin in Noncirrhotic Subjects With Chronic Hepatitis C Who Have Relapsed
SCV-07 (γ-D-glutamyl-L-tryptophan) is a new immunomodulatory compound that has been developed and patented both for composition and immunomodulatory use and is a synthetic dipeptide.
- Trial name
- NCT00968357
- Testing
- SCV-07
- Where
- 16 sites in United States
- Volunteers
- 40 people
- Sponsor
- SciClone Pharmaceuticals
Chronic Hepatitis C
Histologic Changes and Noninvasive Assessment in Hepatitis C Patients Treated with Peginterferon Alpha-2a and Ribavirin
•The purpose of this study is to compare the performance between liver biopsy and non-invasive fibrosis assessments evaluating anti-fibrotic efficacy of peginterferon plus ribavirin in patients with hepatitis C pre- and…
- Trial name
- NCT01634919
- Testing
- chronic hepatitis C
- Where
- 2 sites in South Korea
- Volunteers
- 55 people
- Sponsor
- Seoul National University Boramae Hospital
Hepatitis C, Opioid Use
The Staying Safe Intervention
The growing population of young people who inject drugs (PWID) is at extremely high risk for HCV infection through the use of contaminated injection equipment, yet, to date, no behavioral intervention has been sufficiently potent…
- Trial name
- Ssafe (NCT03418636)
- Testing
- Staying Safe (Ssafe), Healthy Living
- Where
- United States
- Volunteers
- 456 people
- Sponsor
- National Development and Research Institutes, Inc.
Hepatitis C, Chronic Hepatitis C
Birth-Cohort Evaluation to Advance Screening and Testing for Hepatitis C
The Birth-Cohort Evaluation to Advance Screening and Testing for Hepatitis C (BEST-C) compares the effectiveness of the birth cohort HCV screening strategy with the current risk-based screening approach to detect previous…
- Trial name
- Best-C (NCT02123212)
- Testing
- Mailer, In-person recruitment, EHR Alert
- Where
- 3 sites in United States
- Volunteers
- 29,607 people, healthy volunteers welcome
- Sponsor
- National Opinion Research Center
Genotype 4 Chronic Hepatitis C Infection
Boceprevir With Peginterferon Alfa-2b and Ribavirin in the Treatment-naive Patients Infected With Genotype 4 Chronic Hepatitis C Infection
Hypothesis Combination of Boceprevir with Ribavirin in treatment-naïve patients with genotype 4 chronic hepatitis C infection will increase the proportion of patients achieving sustained viral response compared to standard…
- Trial name
- NCT01653236
- Testing
- Boceprevir, Peginterferon alfa-2b, ribavirin
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Theodor Bilharz Research Institute
Hepatitis C, Opioid-Related Disorders
The Kentucky Viral Hepatitis Treatment Study
The overarching goal of the Kentucky Viral Hepatitis Treatment Project (KeY Treat) is to increase hepatitis C virus (HCV) treatment access and delivery in a rural Appalachian community, which is in the midst of the…
- Conditions
- Hepatitis C, Opioid-Related Disorders, Injection Drug Use
- Trial name
- KeY Treat (NCT03949764)
- Testing
- Sofosbuvir/velpatasvir (Epclusa®)
- Where
- United States
- Volunteers
- 380 people
- Sponsor
- Jennifer Havens
Hepatitis C
Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With Sofosbuvir
The primary objective of this study is to estimate, in HCV genotype 1 or 4-infected patients who failed a prior DAA bitherapy with Sofosbuvir, the efficacy of a treatment with Grazoprevir/Elbasvir, Sofosbuvir and Ribavirin in the…
- Trial name
- NCT02647632
- Testing
- Grazoprevir/Elbasvir, Sofosbuvir, Ribavirin
- Where
- 13 sites in France
- Volunteers
- 26 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Chronic Hepatitis C
Effect of ASV and DCV Therapy on the Quality of Immune Status in Chronic HCV Patients
Rationale: Chronic HCV infection is characterised by a weak HCV specific CD8+ T cell response, due to continuous pressure of high viral load.
- Trial name
- ImmunoDual (NCT02282709)
- Testing
- Daclatasvir, asunaprevir
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- Foundation for Liver Research
Hepatitis C Virus
TMC435-TiDP16-C126 - Trial to Investigate the Effect of Severe Renal Impairment on the Pharmacokinetics and Safety of TMC435
The purpose of this study is to assess the steady-state pharmacokinetics of TMC435 in participants with severe renal impairment and to compare these with the TMC435 pharmacokinetics in matched participants with normal renal…
- Trial name
- NCT01381835
- Testing
- TMC435
- Where
- Czechia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Hepatitis C, Chronic
An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease
The purpose of this study is to assess the efficacy of a 12-week regimen containing simeprevir, daclatasvir and sofosbuvir in participants with decompensated liver disease (the liver function is insufficient) due to genotype 1 or…
- Trial name
- NCT02262728
- Testing
- Simeprevir, Daclatasvir, Sofosbuvir
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Janssen Research & Development, LLC
Cancer, Liver Cirrhosis
Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer
To acquire blood samples from subjects for various purposes, including: i) determining the sensitivity and specificity of select DNA methylation markers for the detection of various types of cancer, ii) identifying benign…
- Conditions
- Cancer, Liver Cirrhosis, Chronic Hepatitis, Hepatitis B
- Trial name
- ELITE (NCT05181826)
- Testing
- Multi-analyte Blood Test
- Where
- 7 sites in United States
- Volunteers
- 1,200 people
- Sponsor
- Helio Genomics
Chronic Hepatitis C Virus
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Velpatasvir in Participants With Chronic HCV Infection
The primary objective of the study is to evaluate the safety, tolerability, and antiviral activity of velpatasvir (formerly GS-5816) in HCV treatment naive participants with genotypes 1-6.
- Trial name
- NCT01740791
- Testing
- Velpatasvir
- Where
- 10 sites in United States, Puerto Rico
- Volunteers
- 103 people
- Sponsor
- Gilead Sciences
Hepatitis C, Chronic
A Study of Ritonavir-Boosted Danoprevir (RO5190591) in Combination With Pegasys and Ribavirin in Patients With Chronic Hepatitis C Genotype 1
This study will evaluate the efficacy, safety and tolerability of danoprevir (RO5190591) plus ritonavir as compared to danoprevir alone or placebo plus ritonavir in patients with chronic hepatitis C genotype 1 receiving Pegasys…
- Trial name
- NCT01185860
- Testing
- danoprevir, peginterferon alfa-2a [Pegasys], ribavirin
- Where
- 4 sites in France, New Zealand and 1 more
- Volunteers
- 59 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C Virus Infection
Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen
The primary objective of this study is to evaluate the efficacy, safety, and tolerability of the treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) fixed dose combination (FDC) ± ribavirin (RBV) in participants with…
- Trial name
- NCT02536313
- Testing
- SOF/VEL/VOX, RBV
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Gilead Sciences
Hepatitis C, Opiate Dependence
Effective Treatment of Hepatitis C in Substance Users
We hypothesize that integrating Hepatitis C into methadone and buprenorphine treatment will improve Hepatitis C outcomes as well as drug treatment outcomes in patients who are addicted to opiates.
- Trial name
- NCT00633243
- Testing
- Modified Directly Observed Therapy (mDOT), Self-Administered Therapy (SAT)
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Yale University
Hepatitis C, Chronic Pain
Efficacy and Safety of Alisporivir Alone or Combined With RBV or PEG in Chronic Hepatitis C Genotype 2 and 3 Treatment-naïve Participants
The study is to investigate whether alisporivir (ALV; DEB025) alone or in combination with either ribavirin (RBV) or peginterferon alfa-2a (PEG) is more efficient compared to standard of care (PEG+RBV) in treatment-naïve…
- Trial name
- NCT01215643
- Testing
- Alisporivir, Peginterferon alfa-2a, Ribavirin
- Where
- 73 sites in United States, Australia and 12 more
- Volunteers
- 340 people
- Sponsor
- Debiopharm International SA
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.